BioSpace News Archive

Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced its second virtual event this year designed to showcase how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces

NASA’s Glenn Research Center and University Hospitals in Cleveland have collaborated to develop new methods and technologies for decontaminating personal protective equipment for aerospace applications and for safeguarding the health of workers caring for patients with coronavirus.

SWORD Health, a digital musculoskeletal and pulmonary therapy provider, today announced the appointment of industry paragon Brian Marcotte to lead their Client Advisory Board.

the U.S. Food and Drug Administration took important action to help facilitate the timely development of safe and effective vaccines to prevent COVID-19 by providing guidance with recommendations for those developing COVID-19 vaccines for the ultimate purpose of licensure.

Repurpose.AI, an AI drug discovery company, today announced the launch of an Open Innovation Partnership with LEO Pharma A/S, a global leader in medical dermatology, to discover and validate drugs to treat inflammatory and dermatology indications.

Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors.

Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the burden of chronic injections for people with rare diseases, today announced that it has commenced an underwritten public offering of its common stock,

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change in the format of its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) from in-person to a virtual-only meeting format due to the continuing public health impact of COVID-19 and to support the health and safety of the Company’s stockholders and attendees.

Synergy CHC Corp (OTCM: SNYR) (the “Company”), a consumer healthcare company, intends to file a Form 15 with the SEC to voluntarily effect the deregistration of its Common Stock.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 26 individuals hired by Sarepta in June 2020.